Innoventric Secures $28.5M and Unveils Groundbreaking Tricuspid Regurgitation Treatment to Help Patients
October 31, 2024
October 31, 2024
ST. LOUIS PARK, Minnesota, Oct. 31 [Category: Medical] -- Medical Alley posted the following news release:
Reduces Treatment Risk By Eliminating the Need for Surgical Valve Replacement and General Anesthesia Which Ensures Shorter Operations
New York, NY October 30, 2024 Innoventric, a leader in transcatheter tricuspid regurgitation (TR) treatment, today announced a $28.5 million Series B funding round to advance its revolutionary cross-caval technology, bringing the to . . .
Reduces Treatment Risk By Eliminating the Need for Surgical Valve Replacement and General Anesthesia Which Ensures Shorter Operations
New York, NY October 30, 2024 Innoventric, a leader in transcatheter tricuspid regurgitation (TR) treatment, today announced a $28.5 million Series B funding round to advance its revolutionary cross-caval technology, bringing the to . . .